Intellia Therapeutics, Inc. - Common Stock (NTLA)
$10.71
0.80 (6.95%)
NTLA Stock Quote Delayed 30 Minutes
3 Gene Editing Stocks with Potential to Transform Medicine
Gene-editing holds substantial promise for treating thousands of diseases – creating incredible opportunities for gene editing stocks.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
943.99M
PE Ratio
-1.97
EPS
-5.44
Volume (Avg. Vol.)
3.86M
Day's Range
$10.45 - $11.86
52-Week Range
$8.96 - $34.87
Dividend & Yield
N/A (N/A)
NTLA Stock Predictions, Articles, and Intellia Therapeutics, Inc. - Common Stock News
3 Gene Editing Stocks That Could Grow Your Wealth
Investors looking for gene editing stocks of cutting edge technology firms should consider these biotech stocks.
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
Explore gene-editing stocks with potential to become multibaggers as the industry advances in treating genetic disorders.
3 Profitable CRISPR Stocks Earning Analysts’ Praise
Revolutionary gene-editing technologies provide promise for investors seeking the most profitable CRISPR stocks today and in the future.
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
Finding undervalued gene editing stocks is easy, but having the patience to stick with them is the challenge
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks.
3 Pharma Stocks Already Ushering in the Next Biotech Boom
So long as diseases afflict the human condition, there will likely always be a need for pharma stocks. Here are three to consider.
The 3 Best Biotech Stocks to Buy in July 2024
For investors looking for promising biotech investments should explore the best biotech stocks to watch in July 2024.
Treasure Hunt: 3 Biotech Stocks Wall Street Hasn’t Discovered Yet
Undiscovered biotech stocks can be risky but rewarding, especially when it involves mid-cap stocks with promise and no profit.
You’ve Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.
The best gene editing stocks to buy are those with strong tehnogical applications and genuine commercialization prospects.
Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich
Gene editing is a game-changer, creating substantial opportunities for some of the leading gene editing stocks.
3 Gene Editing Stocks That Could Make Your Grandchildren Rich
Explore gene-editing stocks with long-term growth potential, offering innovative solutions to previously untreatable conditions.
NTLA Stock Earnings: Intellia Therapeutics Beats EPS, Beats Revenue for Q1 2024
NTLA stock results show that Intellia Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
